Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Tougeron

Showing results (181-190 of 235) with videos related to

Pageof 24
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 21, 2025
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitorsClaire Gallois, Margherita Ambrosini, Sara Lonardi, et al.
Clinics and Research in Hepatology and Gastroenterology|December 14, 2024
Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD studyVictoire Dabout, Laurent Mineur, David Tougeron, et al.
Journal for Immunotherapy of Cancer|October 30, 2025
Efficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world studyEmily Alouani, Julien Taieb, David Tougeron, et al.
Journal of the National Cancer Institute|February 4, 2016
Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO StudyDavid Tougeron, Guillaume Mouillet, Isabelle Trouilloud, et al.
European Journal of Cancer (Oxford, England : 1990)|March 4, 2019
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validationsCindy Neuzillet, Andrea Casadei Gardini, Bertrand Brieau, et al.
International Journal of Molecular Sciences|April 23, 2022
Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal CancersCamille Evrard, Stéphane Messina, David Sefrioui, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 3, 2021
Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trialClaire Gallois, Jean-François Emile, Stefano Kim, et al.
British Journal of Cancer|December 15, 2023
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world studyClémence Flecchia, Edouard Auclin, Emily Alouani, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2026
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 studyMélanie Dos Santos, Justine Lequesne, Guillaume Piessen, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 16, 2017
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumoursCôme Lepage, Laetitia Dahan, Nadia Bouarioua, et al.
Pageof 24

Showing results (181-190 of 235) with videos related to

Sort By:
Pageof 24
European Journal of Cancer (Oxford, England : 1990)|July 21, 2025
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitorsClaire Gallois, Margherita Ambrosini, Sara Lonardi, et al.
Clinics and Research in Hepatology and Gastroenterology|December 14, 2024
Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD studyVictoire Dabout, Laurent Mineur, David Tougeron, et al.
Journal for Immunotherapy of Cancer|October 30, 2025
Efficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world studyEmily Alouani, Julien Taieb, David Tougeron, et al.
Journal of the National Cancer Institute|February 4, 2016
Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO StudyDavid Tougeron, Guillaume Mouillet, Isabelle Trouilloud, et al.
European Journal of Cancer (Oxford, England : 1990)|March 4, 2019
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validationsCindy Neuzillet, Andrea Casadei Gardini, Bertrand Brieau, et al.
International Journal of Molecular Sciences|April 23, 2022
Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal CancersCamille Evrard, Stéphane Messina, David Sefrioui, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 3, 2021
Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trialClaire Gallois, Jean-François Emile, Stefano Kim, et al.
British Journal of Cancer|December 15, 2023
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world studyClémence Flecchia, Edouard Auclin, Emily Alouani, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2026
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 studyMélanie Dos Santos, Justine Lequesne, Guillaume Piessen, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 16, 2017
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumoursCôme Lepage, Laetitia Dahan, Nadia Bouarioua, et al.
Pageof 24